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ABSTRACT
Ciprofloxacin is recommended for complicated urinary tract infection (UTIs) 
caused by multidrug-resistant pathogens included Escherichia coli. However, its 
optimum dose for UTIs remains uncertain that may cause the bacterial resistance. 
This study was conducted to evaluate the effects of ciprofloxacin concentrations 
on the resistance of E. coli. The in vitro pharmacokinetic/pharmacodynamic (PK/
PD) models of ciprofloxacin 750 mg oral dose twice a day for one daywas compared 
to that dose of 500 mg twice a day for three days.Pharmacokinetic parameters 
i.e.AUC0-24 and Cmax. and pharmacodynamic parameter i.e. MIC of ciprofloxacin 
against E. coli which previously had MIC of 0.5 µg/mL were determined. The PK/
PD parameters combination of ciprofloxacin included AUC0-24/MIC, Cmax/MIC, and 
T>MIC ratio were used to evaluate its antimicrobial activities which was measured 
based on kill and re-growth rates of bacterial colony after the ciprofloxacin 
administration. The result showed that MIC value against E. coli increase to 8-16 
and 32-64 µg/mL after ciprofloxacin 750 and 500 mg administration, respectively, 
indicating the emergence of resistance. Both doses of ciprofloxacin were able 
to reduce the number of bacterial colony in the first two hours administration. 
However, after two hours administration, those both doses could make re-growth 
of bacterial colony. The value of AUC0-24/MIC (120.42±1.27 vs.92.62±9.36), Cmax/MIC 
(4.75±0.21 vs. 3.26±0.30), and (T>MIC 89.58±7.22 vs. 76.39±9.39) after ciprofloxacin 
administration at dose of 750 mg were higher than those at dose of 500 mg. The 
increase of AUC0-24/MIC and Cmax/MIC values could reduce the number of bacteria 
colony, however could not for T>MIC value. In conclusion, the AUC0-24/MIC and Cmax/
MIC parameters of ciprofloxacincan be used to evaluate its activity. In addition, 
ciprofloxacin twice per day at dose 500 mg for three days and 750 mg for one day 
are not different in the inhibition of E. coli resistance emergence.
ABSTRAK
Siprofloksasin direkomendasikan untuk infeksi saluran kemih dengan kompliaksi 
(ISK) yang disebabkan pathogen resistensi multipel obat termasuk Escherichia 
coli. Namun demikian, dosis optimumnya untuk ISK masih belum pasti sehingga 
kemungkinan dapat menyebabkan resistensi bakteri. Penelitian ini bertujuan untuk 
mengkaji efek kadar siprofloksasin pada resistensi E. coli. Model farmakokinetik 
dan farmakodinamik (PK/PD)in vitrosiprofloksasin 750 mg dosis oral dua kali 
sehari satu hari dibandingkan dengan dosis dosis 500 mg dua kali sehari tiga hari. 
Parameter farmakokinetik yaitu AUC0-24 dan Cmaks dan parameter farmakodinamik 
yaitu MIC siprofloksasin terhadap E. coli, yang sebelumnyatelah diukur 
mempunyai nilai MIC 0,5 µg/mL. Kombinasi parameter PK/PD siprofloksasin yaitu 
rasio AUC0-24/MIC, Cmax/MIC, dan T>MIC digunakan untuk mengevaluasi aktivitas 
antimikrobialnya yang ditetapkan berdasarkan daya bunuh koloni bakteri setelah 
pemberian siprofloksasin. Hasil penelitian menunjukkan bahwa nilai MIC terhadap 
E. coli meningkat menjadi 8-16 dan 32-64 µg/mL setelah pemberian berturut-
turut siprofloksasin dosis 750 dan 500 mg yang mengindikasikan munculnya 
resistensi. Kedua dosis siprofloksasin dapat menurunkan jumlah koloni bakteri 
pada dua jam pertama pemberian. Namun demikian, setelah dua jam pemberian 
kedua dosis siprofloksasin dapat membuat koloni bakteri tumbuh kembali. Nilai 
AUC0-24/MIC (120,42±1,27 vs. 92,62±9,36), Cmax/MIC (4,75±0,21 vs. 3,26±0,30), dan 
(T>MIC 89,58±7,22 vs. 76,39±9,39)setelah pemberian siprofloksasin dosis 750 
mg lebih tinggi dari dosis 500 mg. Kenaikan nilai AUC0-24/MIC dan Cmax/MIC dapat 
menurunkan jumlah koloni bakteri, namun tidak untuk kenaikan nilai T>MIC. 
Dapat disimpulkan, siprofloksasin dua kali sehari dosis 500 mg selama tiga hari 
atau 750 mg sehari tidak berbeda dalam menghambat munculnya resistensi E. coli.
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INTRODUCTION
New antibiotic discovery and 
development have slowed alarmingly 
in recent decades. Otherwise, bacterial 
resistance to antimicrobial agents is a 
growing problem due to not optimal of 
the dose regimensof the antimicrobial 
agents. Therefore, effort to optimize the 
dose regimen of antimicrobial agentsis 
urgently needed in order to obtain optimal 
clinical benefit and minimize the risk of 
multidrug resistant bacterial pathogens.1 
To obtain the optimal of the dose regimen, 
linking the concentration-time course 
at the site of action and the antibiotic 
susceptibility (pharmacokinetic and 
pharmacodynamic relationship) should 
be considered.2,3
In vivo pharmacokinetic and 
pharmacodynamic relationship (PK/
PD) models of an antibiotic could be 
conducted in animal. The in vivo PK/
PD models provide similar growing 
conditions for bacteria, closely 
imitatingthe characteristics of a human 
infection, and clearly defining the 
endpoint of aninfection (cure or death) 
and comparable tothat in humans.4 
A significant disadvantage of animal 
modelsis differences in the PK, which 
limit sophisticated scaling methods 
for transferring data from animals to 
humans.5
In vitro PK/PD models have  its 
own advantages. This models can be 
applied without influenced by bacterial 
phenotype at the site of infection, in vivo 
bacterial growth phase, host immunity, 
infection site, and pharmacokinetics 
of the antibiotics. In addition, this 
method allows  resistance analyses, 
determination of time-kill behaviour, 
and identification and optimization 
of PK/PD indices and breakpoints.3,6 
Therefore, the in vitro PK/PD models are 
often applied before the in vivo PK/PD 
models conducted.
Urinary tract infection (UTI) is an 
infection that affects part of the unrinary 
tract. The UTIs occur more commonly in 
women than men, with half of women 
having at least one infectionin their 
lifetimes. The most common cause of 
UTIs is Escherichia coli which reaches 
80% of UTI cases.7 Amoxicillin has 
traditionally been a first-line antibiotic 
for UTI, however increased rates of 
E. coli resistance have made it a less 
acceptable choice. Fluoroquinolones 
is useful for UTIs caused by multidrug-
resistantpathogens.8 Ciprofloxacin has 
been recommended for complicated 
UTIs and pyelonephritis caused by E. coli 
in patients one to 17 years old.9
The dose regimens of ciprofloxacin 
for UTIs were investigated by some 
authors. However the optimum dose 
regimen of ciprofloxacin for UTIs 
remains uncertain. Ciprofloxacin can be 
administered in doses of 500 mg twice 
per day or 1000 mg once per day for 
seven days.10 In addition, ciprofloxacin 
dose of 400-500 mg twice per day for 
10-14 days has been recommended. 
Although in short-course therapy for 
seven days with the same dose of 
the ciprofloxacin is effective for the 
treatment of uncomplicated UTIs.11,12
Milo et al.13  reported no difference in 
outcome regarding symptoms between 
3-day and 5-10 day antibiotic regimens for 
uncomplicated UTI in women. However, 
the longer regimen was more common 
in adverse effects although it was more 
effective at eradicating bacteriuria. 
Futhermore, Lutters and Vogt‐Ferrier14 
reported that resolution of short‐term 
bacteriuria of UTI in older women was 
better in the longer course treatment 
group compared with the shorter term 
treatment group. However, there was 
no difference in long‐term bacteriuria or 
clinical cure rate.
This study was conducted to 
evaluate the effects of ciprofloxacin 
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concentrations on the resistance of 
uropathogen E. coli. The in vitro PK/
PD models of ciprofloxacin oral dose of 
750 mg twice per day for one day was 
compared to thatdose of 500 mg twice 
per day for three days in this study. 
MATERIALS AND METHODS
Strains and antibiotic
Escherichia coli strain isolated from 
urinary tract infection patients was 
used in this study. The uropathogenic 
E. Coli isolate was identified and 
cultured in Laboratory of Department 
of Microbiology, Faculty of Medicine, 
Universitas Muhammadiyah Semarang. 
Furthermore, susceptibility of the E. coli 
strain to ciprofloxacin was determined 
using broth dilution method. The E. 
coli strain was ciprofloxacin-sensitive 
strain with MIC value of 0.5mg/mL 
according to EUCAST. Ciprofloxacin 
was obtained from pharmaceutical 
companies PT Phapros Tbk Semarang, 
Indonesia. Ciprofloxacin stock solution 
was prepared with 4% NaOH in sterile 
distilled water and stored at 4oC before 
use.
MIC determination
The MIC of ciprofloxacin against 
uropathogenic E. Coli isolate was 
determined using the microdilution 
method according to the laboratory 
standard guideline. Bacteria from 
clones werepicked from freshly culture 
plates and then diluted with Meuller-
Hinton Broth (MHB) liquidmedia to 
final concentration of 108CFU/mL. Serial 
dilutions of ciprofloxacin ranged from 
0.008 to 32 µg/mLwere then prepared 
by diluting the stock solution with MHB 
media. One hundred uL of the diluted 
bacterial suspension was added to tube 
containing 1900 uL of the serial dilutions 
of ciprofloxacin to yield the appropriate 
density (5x106 CFU/mL)  and the incubated 
for 18 to 24 h at 37oC. As control was a 
tube containing the diluted bacterial 
suspensions without ciprofloxacin. MICs 
were defined as the lowest concentration 
of ciprofloxacin that completely inhibits 
the growth of the organism as detected 
by the unaided eye.
In vitro kineticmodel
An in vitro kinetic one-
compartmentmodel as described 
previously was used to simulate the 
serum ciprofloxacin-time curve in 
humans.15,16 The model consists offresh 
medium reservoir, central compartment, 
andliquid waste storage compartment 
(FIGURE 1). The medium is pumped 
from the fresh medium reservoir to the 
central compartment by a peristaltic 
pump. A filter membrane with pore 
size of 0.45 µmis placed at the bottom of 
central compartment to prevent bacteria 
from flowing out with the medium. A 
magnetic stirrer is attached to the central 
compartment, ensuring homogenous 
mixing of the culture and preventing 
the membrane poresbeing blocked by 
bacteria. The central compartment has 
also sampling port to facilitate repeated 
sampling.During the experiments, the 
apparatuswas placed in a thermostatic 
room at 35°C. Fresh MHB medium 
pumped intothe central compartment 
displaces an equal volume of liquid, 
which flows out through and enters the 
waste medium container.
194
J Med Sci, Volume 52, Number 3, 2020, July: 191-204
FIGURE 1. Equipment for in vitro kinetic model study
Ciprofloxacin added to the central 
compartment was diluted according 
to the first order kinetics C = Cmax x 
e-2kt, where C was the ciprofloxacin 
concentration at time t, Cmaxwas the 
initial antibiotic concentration, k was 
the rate of elimination and t was the time 
elapsed since cirpofloxacin addition.
Pharmacokinetics in healthy volunteers 
receiving oral dose of ciprofloxacin 
(750mg twice per day for one day and 
500mg twice per day for three days) were 
simulated in this study. 
In vitro PK/PD study of ciprofloxacin
The culture of E. coli isolates in 
concentration of 5 x 108 CFU was added 
to the central compartment containing 
fresh MHB medium and then incubated 
at 35oC for three days. Followed after this 
incubation period, the ciprofloxacin at 
concentration corresponding to a dose 
of 750mg twice per day for one day or 
500mg twice per day for three days were 
added into the central compartment and 
the pump was turned on.
For the PD analysis, a 200µL sample 
was then taken  through the sampling port 
at the following time points: 0, 2,7,12,15, 
and 24h for the dose of ciprofloxacin 
of 750mg and 0, 2, 7, 12, 24, 36, 48, and 
72 h for the dose of ciprofloxacin of 
500mg. Samples were properly diluted 
with MHB, and then 10µL aliquots of 
the diluted samples were poured on 
to Meuller-Histon agar (MHA) plates 
and incubated at 35oC for 24 h. After 
incubation, colonies of the samples were 
counted and the log-transformed colony 
counts (y axis) obtained were plotted 
against time (x axis) for the time-kill 
curve. 
For PK analysis, a 200µL sample was 
taken at the following time points: 0, 0.5, 
1, 1.5, 2, 4, 7, 11, 12, 12.5, 13, 13.5, 15, 23, 24, 
26 and 28 h for the dose of ciprofloxacin 
of 750 mg and 0, 0.5, 1, 1.5, 2, 4, 7, 11, 12, 
12.5, 13, 13.5, 15, 23, 24, 24.5, 25, 25.5, 
36, 36.5, 37, 37.5, 48, 48.5, 49, 49.5, 60, 
60.5, 61, 61.5 and 72 h for the dose of 
ciprofloxacin of 500mg. The sample was 
stored at 2-8oC until the ciprofloxacin 
concentration was determined. 
Determination of ciprofloxacin 
concentration 
The determination of ciprofloxacin 
concentration was performed 
using a high performance liquid 
chromathography (HPLC) method. The 
HPLC instrument (Shimadzu, Kyoto, 
Japan) was equipped with a model series 
LC-10 AD VP, Rheodyne 7725i injector 
with a 100µL loop and SPD-10A UV-
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Visible detector. A reversed-phase C18 
column (Eurospher; 4.6µm, 250mm x 
4.6mm i.d) was used as the stationary 
phase for separation and quantitation. 
The mobile phase consisted of phosphate 
buffer-acetonitr i le - tr iethylamine 
(65:35:0.6 v/v/v) pH adjusted to 3.0 ± 
0.05 with phosphoric acid. A flow rate 
of 0.8mL/min was maintained. The 
injection volume was 20µL. The detector 
was set at 275nm. A 200µL sample was 
precipitated with 200µL acetonotrile and 
then was vortexed for one min. After 
centrifugation at 5000 rpm for 10 min, 
the supernatant was transferred to a 
2-mL polyethylene tube and 20µL of the 
supernatant was injected into the HPLC 
system. All assays were conducted in 
triplicate and the correlation coefficient 
for standard curves was always  ≥0.99. 
The lower limit of quantitation was 
4.12µg/mL and the coefficient of 
variation was 7.06%.
PK/PD analysis
The pharmacokinetic data included 
Cmax (the maximum concentration of 
ciprofloxacin in central compartment), 
AUC0-24 (the area under the concentration-
time curve for ciprofloxacin from h 0 to 
24), T>MIC (the percentage of a 24-h period 
in which the ciprofloxacin concentration 
exceeds the MIC) were calculated using 
standard method. Furthermore, the PK/
PD parameters included Cmax/MIC, AUC0-
24/MIC and T>MIC were determined using 
the pharmacokinetic values and MIC data 
in each experiment. The relationship 
between the PK/PD parameters and a log 
E. coli colony at final phase of growth 
rate as well as of final phase of the kill 
rate were evaluated.
Data were expressed as the mean 
± standard deviation (SD). Statistical 
comparisons were conducted using 
Student’s t-test. The differences between 
the parameters after ciprofloxacin 
oral dose of 750mg and 500mg were 
considered significant at a value of <0.05.
RESULTS
MIC of ciprofloxacin against E. coli 
isolates
The original MIC of ciprofloxacin 
against uropathogenic E. coli isolates 
was 0.5µg/mL. With this MIC value, the 
isolates was considered susceptible 
to ciprofloxacin. After ciprofloxacin 
addition at concentration corresponding 
to a doseof 750mg twice per day for one 
dayor 500mg twice per day for three 
days, the isolates developed loss of 
susceptibility with MICs ranging from 8.0 
to 16.0µg/mL and from 32.0 to 256.0µg/
mL, respectively.
In vitro pharmacokinetic profile
In vitro pharmacokinetic profile of 
ciprofloxacin at dose of 750mg twice 
per day for one day and at dose of 
500mg twice per day for three days is 
presented in FIGURE 2, where as their 
pharmacokinetic values are presented 
in TABLE 1. 
TABLE 1. Pharmacokinetic parameters (mean ± SD) of 
ciprofloxacin at dose of 750 and 500mg 
Parameter Dose 750 mg Dose 250 mg
Cmax (µg/mL) 2.25 ± 0.150 1.84 ± 0.106
Tmax (h) 1.58 ± 0.200 1.53 ± 0.128
t1/2 (h) 4.69 ± 0.625 5.41 ± 0.625
AUC0-24 (µg/mL. h) 59.25 ± 1.72 43.29 ± 6.19
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FIGURE 2. In vitro pharmacokinetic profile of ciprofloxacin at A) dose of 750mg 
twice per day for one day and B) dose of 500mg twice per day for three 
days
In vitro pharmacodynamic profile
In vitro pharmacodynamic profile 
of ciprofloxacin at dose of 750mg twice 
per day for one day and at dose of 
500mg twice per day for three days as 
well as control is presented in FIGURE 
3. The number of  bacterial colonies 
significantly decreased at the first two 
hours after ciprofloxacin administration 
at doses of 750 and 500mg and then 
significantly increased two hours after 
ciprofloxacin administration (p<0.05). 
Moreover, the E. coli growth rate after 
ciprofloxacin at dose of 750 mg was 
significantly lower than that at dose of 
500mg (p<0.05). In contrast, the number 
of  bacterial  colonies significantly 
increased during control administration. 
It was indicated that the E. coli kill rate 
phase is observed at the first two hours, 
where as the E. coli re-growth rate 
phase is observed after two hours of 
ciprofloxacin administration. 
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FIGURE 3. Changes in the number of log E. coli colony vs. time 
in the control  treatment,  and after  the ciprofloxacin 
administration at doses of 750 and 500mg. 
TABLE 2. Kill rate and growth rate slope (mean ± SD) after the control 
or  the ciprofloxacin administration at dose of 500mg twice 
day for 3 days, or 750mg twice day for 1 day
Control











slope on 1 day
0.098 -1.31 0.063 -1.51 0.034
0.104 -1.32 0.079 -1.60 0.045
0.104 -1.36 0.076 -1.60 0.035
0.102±0.003 -1.33±0.026 0.073±0.009 -1.57±0.05 0.038±0.006
The kill rate slope 2 hours and 
re-growth  rate slope on 1 day were 
calculated and used as in vitro of 
pharmacodynamic parameters to 
describe antimicrobial activities. The 
results are presented in TABLE 2. 
To investigate the PK/PD 
relationship, the PK/PD parameters 
combination of ciprofloxacin included 
AUC0-24/MIC, Cmax/MIC, and T>MIC ratio 
and its antimicrobial activities included 
the kill rate slope 2 hours and re-growth 
rate slope on 1 day were analyzed. The 
results are presented in TABLE 3-5 and 
FIGURE 4-6.
A positive relationship between 
AUC0-24/MIC with the number of log E. 
coli  colony at the final phases of growth 
rateand kill rate was observed (TABLE 
3 and FIGURE 4). The increase of the 
AUC0-24/MIC ratio might increase the 
antimicrobial activity of ciprofloxacin 
as indicated by greater decreased in the 
number of log E. coli colony.
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TABLE 3. AUC0-24/MIC parameters of dose of ciprofloxacin 500 and 
750mg and the decrease or increase in the number of log 
E. coli colony kill rate and growth rate phases
Ciprofloxacin AUC0-24/MIC
Log colony 
decrease in kill 
ratephase
Log colony increase/
decrease in growth 
ratephase
Dose 500mg
1 86.00 2.62 -2.51
2 99.24 2.63 -3.27
3 74.48 2.72 -3.16
Mean ± SD 92.62±9.36 2.625±0.007 -2.89±0.537
Dose 750mg
1 121.32 3.02 0.10
2 119.52 3.20 -0.38
3 114.66 3.20 0.06
Mean ± SD 120.42±1.27 3.11±0.13 -0.14±0.34
(A) (B)
FIGURE 4. Linear regression relationship between AUC0-24/MIC and the number of log  E. coli 
colony at final phase of the growth rate (A) Linear regression relationship between 
AUC0-24/MIC and the number of log E. coli colony at final phase of the kill rate (B)
A positive relationship between 
Cmax/MIC with the number of log E. coli 
colony at the final phases of growth rate 
and kill rate was also observed (TABLE 
4 and FIGURE 5). However, significantly 
different in the phase of kill rate at 2 
hours after ciprofloxacin administration 
at dose of 750mg and that of 500mg was 
observed. The Cmax at dose of 750mg 
was significantly higher than that at 
dose of 500mg resulting higher Cmax/
MIC ratio and higher antimicrobial 
activity as demonstrated by the greater 
decrease in the number of log E. coli 
colony in the first 2 hours ciprofloxacin 
administration. 
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TABLE 4. Cmax/MIC parameters of dose of ciprofloxacin 500 and 
750mg and the value respectively decrease or increase in 




decrease in kill 
ratephase
Log colony increase/
decrease in growth 
rate phase
Dose 500mg
1 3.22 2.62 -2.51
2 3.58 2.63 -3.27
3 2.98 2.72 -3.16
Mean ± SD 3.26±0.30 2.66±0.05 -2.98±0.41
Dose 750mg
1 4.86 3.02 0.10
2 4.88 3.20 -0.38
3 4.50 3.20 0.06
Mean ± SD 4.75±0.21 3.14±0.10 -0.07±0.27
(A) (B)
FIGURE 5. Linear regression relationship between Cmax/MIC and the number of log E. coli 
colony at final phase of the growth rate (A) Linear regression relationship between 
AUC0-24/MIC and the number of log E. coli colony at final phase of the kill rate (B)
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TABLE 5. T>MIC parameters of dose of ciprofloxacin 500 and 750mg 
and the value respectively decrease or increase in the 




decrease in kill 
ratephase
Log colony increase/
decrease in growth 
rate phase
Dose 500mg
1 77.08 2.62 -2.51
2 85.41 2.63 -3.27
3 66.67 2.72 -3.16
Mean ± SD 76.39±9.39 2.66±0.05 -2.98±0.41
Dose 750mg
1 93.75 3.02 0.10
2 93.75 3.20 -0.38
3 81.25 3.20 0.06
Mean ± SD 89.58±7.22 3.14±0.10 -0.07±0.27
(A) (B)
FIGURE 6. Linear regression relationship between T>MIC and the number of log E. coli colony 
at final phase of the growth rate (A) Linear regression relationship between AUC0-24/
MIC and the number of log E. coli colony at final phase of the kill rate (B)
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DISCUSSION
The result of the PK/PD parameters 
relationship analysis showed the 
emergence of E. coli resistance after 
ciprofloxacin at dose of 750mg twice a 
day for one day or at dose of 500mg twice 
a day for three days. It was demonstrated 
by the increase of MIC value against 
E. Coli to be 8-16 and 32-64µg/mL 
after ciprofloxacin 750 and 500mg 
administration, respectively. The both 
doses of ciprofloxacin administration 
could notinhibit the emergence of  E. coli 
resistance. Although, the increase of MIC 
value ciprofloxacin after administration 
at dose 750mg was lower that at dose 
500mg.
The in vitro PK/PD model to evaluate 
antimicrobial activity of ciprofloxacin 
against E. coli has been reported 
previously. Fantin et al.15 reported that 
the resistant commensal E. coli from 
fecal and pharyngeal emerge during 
treatment with six dose of ciprofloxacin. 
However, the resistance emergence is not 
associated with the PK/PD parameters.
The different of AUC/MIC, Cmax/MIC, and 
T>MIC ratio values does not affect the 
emergence of  E. coli resistance which 
not indicate significantly different across 
the different ciprofloxacin dosages. 
Khan et al.16 developed an in vitro PK/PD 
model describing killing kinetics for E. 
coli following exposure to ciprofloxacin. 
This model successfully characterizes 
time-kill curve for both will type and the 
six E. coli mutants based on the MIC of 
ciprofloxacin.
Antibiotic resistance can occur due 
to three main mechanisms as follow 
1) the transfer of resistant genes from 
resistant to susceptible micro organisms; 
2) genetic adaptation (changing the drug 
target); and 3) phenotype adaptation, 
such as modification of efflux pumps. 
Resistance mechanisms of genetic and 
phenotypic adaptation can be triggered 
by de novo resistance that occurs quickly 
during therapy.17,18
Escherichia coli could be resistant 
to multiple antibiotics during minimal 
exposure of antibiotics levels due 
to horizontal gene transfer (HGT) of 
resistant strains to susceptible strains. 
Resistance is often associated with a 
reduction in ‘fitness’ of bacteria, which 
means the ability of a genotype or 
individuals of bacteria to survive and 
reproduce. Decreased use of antibiotics 
will reduce the environmental pressure 
on the bacteria and reduce the amount 
of acquired resistance. The speed of 
bacterial resistance is affected by the 
speed of de novo mutations and HGT 
from carrier of resistance determinants. 
The most frequent mutation is to 
change the target action of antibiotics 
and increasing antibiotic efflux. Gene 
amplification, decreased gene expression 
of the target antibiotics, and changes 
enzymes for the drugs modification 
are other mechanisms involving in 
microbial resistance. HGT-related 
mechanisms include modification of the 
drug itself, the target protection, bypass 
resistance (change in metabolic phase 
that inhibited by antibiotic), and the 
acquisition of efflux pumps. The increase 
MIC value to ≥ 32µg/mL against E. coli 
is associated with mutations of gyrA 
and parC or a combination mutation 
of marR, gyrA, and parC. Where as, the 
MIC value < 1µg/mL is associated with 
gyrA gene mutation alone or mutation 
combination of marR and gyrA.19 In 
addition, it was reported that de novo 
E. coli resistance is associated with 
the sub optimal concentration due to 
enfloksasin use as demonstrated by the 
increase of its MIC value.20 Some studies 
reported that the ratio of Cmax/MIC and 
AUC0-24/MIC should reach between 10-
12 and 100-125, respectively to achieve 
therapeutic efficacy of fluoroquinolones 
against Gram – bacilli infections and to 
prevent emergence of resistance.21 The 
emergence of Gram-bacilli resistance 
80% to ciprofloxacin was reported when 
the ratio of Cmax/MIC and AUC0-24/MIC < 8 
and < 100, respectively. This emergence 
of resistance decreased to be 10% (8 time 
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prevention), if the ratio of Cmax/MIC and 
AUC0-24/MIC > 8 and ≥ 100, respectively.
22 
Other study reported that the ratio of 
AUC0-24/MIC <100 cause 86% of developed 
patient resistance, however if the ratio ≥ 
100, the incidence of resistance decrease 
to be 9%. The emergence of resistance is 
an important factor ofa clinical failure 
therapy.23 It was reported that the ratio 
AUC0-24/MIC should be >250 to provide 
the rapid Gram-bacilli elimination.24
In this study, the ratio of Cmax/
MIC was < 8 after administration of 
ciprofloxacin at dose of 500 and 750mg. 
Although the ratioof AUC0-24/MIC was 
>100 at dose of 750mg, it could not 
prevent the emergence of uropathogen 
E. coli resistance. Moreover, a regrowth 
rate phase of uropathogen E. coli was 
still observed at dose of 750mg.
Zelenitsky and Ariano25 reported that 
among 178 Enterobacteriacea infection 
cases treated with ciprofloxacin, 8 cases 
had failed therapy with 3 cases of them 
(37.5%) were infection of uropathogen 
E. coli. The treatment failure might 
be due to low the ratio of AUC0-24/MIC 
of ciprofloxacin. The ratio of AUC0-
24/MIC≥ 250 indicated the success of 
therapy (success rate 91.4%). If  the 
ratio decreased to be< 250, the risk of 
treatment failure increased 27.8 times 
higher.
CONCLUSION
In conclusion, the AUC0-24/MIC and 
Cmax/MIC parameters of ciprofloxacin 
can be used to evaluate its antimicrobial 
activity against uropathogen E. coli. In 
addition, ciprofloxacin twice per day at 
dose 500mg for three days and 750mg for 
one day are not different in the inhibition 
of E. coli resistance emergence. 
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